Mefoxil 1g/Vial (Cefoxitin Sodium)

Cefoxitin Sodium is a second‑generation cephalosporin antibiotic used to treat infections caused by susceptible bacteria.

• Respiratory tract infections: effective for community‑acquired pneumonia and acute bronchitis caused by susceptible organisms.
• Urinary tract infections: used to eradicate Gram‑negative uropathogens in uncomplicated and complicated UTIs.
• Skin and soft tissue infections: treats cellulitis, wound infections, and abscesses due to susceptible bacteria.
• Intra‑abdominal infections: indicated for peritonitis, intra‑abdominal abscesses, and postoperative infections.

• Cefoxitin Sodium exerts a bactericidal effect by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis of susceptible Gram‑positive and Gram‑negative organisms. The molecule also shows resistance to many β‑lactamases, enhancing its activity against β‑lactamase‑producing bacteria. The drug’s time‑dependent killing profile supports dosing intervals that maintain plasma concentrations above the minimum inhibitory concentration.

Cefoxitin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Diarrhea: mild to moderate watery stools.
• Nausea: occasional feeling of queasiness.
• Vomiting: transient episodes.
• Injection site pain: discomfort at the IV or IM site.
• Rash: erythematous skin eruption.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Anaphylaxis: severe, potentially life‑threatening allergic reaction.
• Stevens‑Johnson syndrome: rare severe skin and mucous membrane disorder.
• Clostridioides difficile‑associated diarrhea: severe colitis following antibiotic use.
• Neutropenia: marked reduction in neutrophil count.
• Thrombocytopenia: low platelet levels leading to bleeding risk.
• Acute renal impairment: sudden decline in kidney function.

Prior to initiating therapy with Cefoxitin Sodium, clinicians should consider several safety precautions to minimize risk.

• Allergy assessment: verify no known hypersensitivity to cephalosporins or penicillins.
• Renal function monitoring: check creatinine clearance and adjust dose in renal impairment.
• Hepatic function monitoring: observe liver enzymes in patients with liver disease.
• Concomitant nephrotoxic drugs: use caution when combined with other renal‑toxic agents.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Cefoxitin Sodium can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Aminoglycosides: increased risk of nephrotoxicity when used together.
• Loop diuretics: heightened ototoxic potential.
• Warfarin: potentiation of anticoagulant effect, may raise INR.
• Probenecid: reduces renal excretion of cefoxitin, increasing plasma levels.
• Live bacterial vaccines: may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: possible reduction in hormonal effectiveness.
• Antacids containing aluminum or magnesium: may affect absorption if given orally.
• NSAIDs: concurrent use may impair renal function, especially in compromised patients.